99735-46-3Relevant articles and documents
Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex
Ghosh, Arun K.,Brindisi, Margherita,Nyalapatla, Prasanth R.,Takayama, Jun,Ella-Menye, Jean-Rene,Yashchuk, Sofiya,Agniswamy, Johnson,Wang, Yuan-Fang,Aoki, Manabu,Amano, Masayuki,Weber, Irene T.,Mitsuya, Hiroaki
, p. 5114 - 5127 (2017/09/26)
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes, we have designed a series of isophthalamide-derived inhibitors incorporating substituted pyrrolidines, piperidines and thiazolidines as P2-P3 ligands for specific interactions in the S2-S3 extended site. Compound 4b has shown an enzyme Ki of 0.025 nM and antiviral IC50 of 69 nM. An X-ray crystal structure of inhibitor 4b-HIV-1 protease complex was determined at 1.33 ? resolution. We have also determined X-ray structure of 3b-bound HIV-1 protease at 1.27 ? resolution. These structures revealed important molecular insight into the inhibitor–HIV-1 protease interactions in the active site.
PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS
-
Page/Page column 44-45, (2011/02/24)
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C-X; X represents hydrogen atom or fluorine atom; R1 is hydrogen atom or a C1 -C3 alkyl group; L represents single bond or a C1 -C6 alkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; R2 represents hydrogen atom or a cyclic group which may be substituted, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
A rapid and convenient synthesis of β-proline
Blanchet, Jér?me,Pouliquen, Mickael,Lasne, Marie-Claire,Rouden, Jacques
, p. 5727 - 5730 (2008/02/09)
A short, reliable, and cheap synthesis of both enantiomers of β-proline, an efficient organocatalyst and an important building block in medicinal chemistry, has been developed in four steps (overall yield: 72%) from the diasteromeric adducts of methyl itaconate and (R)-α-methylbenzylamine. The key step involves the chemoselective reduction of a lactam group in the presence of a benzyl ester.
